It will be informative for future studies to definitively measure the frequency of T cells in JMML patients and to assess the relative contribution of their CD4+ and CD8+ cells as well as their naïve and effector subsets. This evidence concerns the gene CD8A and juvenile myelomonocytic leukemia.